INHBA

Across TCGA pan-cancer cohorts, INHBA Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated INHBA data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher INHBA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated INHBA expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCS, HNSC, and PAAD are the cancer types where INHBA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.104	0.688	<.001	36	view →
HNSC	OS	Median	All	0.192	0.661	.010	27	view →
PAAD	OS	Median	All	0.132	0.613	.002	15	view →
LGG	OS	Median	All	0.195	0.896	<.001	12	view →
BLCA	OS	Median	IV	0.153	0.599	.018	9	view →
READ	DFS	Median	II,III,IV	0.082	0.818	.001	6	view →
UCEC	DFS	Median	All	0.955	0.828	.030	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LIHC	OS	Median	All	0.258	0.773	.018	3	view →
LUAD	OS	Median	All	0.443	0.678	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

INHBA–UCS (OS)

Open the UCS breakdown →